ArticleMedComm2026

Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer.

Xiaoxiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.